Literature DB >> 17047385

Acromegaly and the cardiovascular system.

Gaetano Lombardi1, Mariano Galdiero, Renata S Auriemma, Rosario Pivonello, Annamaria Colao.   

Abstract

Acromegaly is characterized by an increased cardiovascular morbidity and mortality. In fact, growth hormone and insulin-like growth factor-I excess induces a specific cardiomyopathy. The heart is involved from the very early stages of the disease in which the hyperkinetic syndrome (high heart rate and increased systolic output) takes place. Frequently, if the disease is untreated for many years or unsuccessfully treated, concentric biventricular hypertrophy and diastolic dysfunction can develop and, at least, lead to diastolic congestive heart failure. Rhythm disturbances and valve dysfunction are also frequently described in acromegaly. The coexistence of other complications, such as diabetes and arterial hypertension, can induce the worsening of acromegalic cardiomyopathy. Control of acromegaly by surgery or pharmacotherapy could improve cardiovascular morbidity thanks to decreasing left ventricular mass and reducing cardiac dysfunction. In conclusion, an early diagnosis and a careful evaluation of cardiac function, morphology and activity seem to be mandatory in acromegaly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047385     DOI: 10.1159/000095530

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  26 in total

1.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

2.  Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry.

Authors:  Christof Schöfl; David Petroff; Anke Tönjes; Martin Grussendorf; Michael Droste; Günter Stalla; Cornelia Jaursch-Hancke; Sylvère Störmann; Jochen Schopohl
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

3.  Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Authors:  Tamara L Wexler; Ronen Durst; David McCarty; Michael H Picard; Lindsay Gunnell; Zehra Omer; Pouneh Fazeli; Karen K Miller; Anne Klibanski
Journal:  Growth Horm IGF Res       Date:  2010-07-03       Impact factor: 2.372

4.  Human growth hormone abuse in male weightlifters.

Authors:  Brian P Brennan; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Am J Addict       Date:  2010-11-12

Review 5.  Characteristics of acromegaly in Korea with a literature review.

Authors:  Jae Won Hong; Cheol Ryong Ku; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2013-09

6.  Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease.

Authors:  A Uçar; Melike Tuğrul; Bülent Oğuz Erol; Ensar Yekeler; Banu Aydın; Seher Yıldız; Kemal Nişli; Firdevs Baş; Şükran Poyrazoğlu; Feyza Darendeliler; Nurçin Saka; Aylin Yetim Şahin; Yasin Yılmaz; Rüveyde Bundak
Journal:  Pediatr Cardiol       Date:  2018-02-01       Impact factor: 1.655

7.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

Review 8.  Current diagnosis of acromegaly.

Authors:  Rocio A Cordero; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.

Authors:  Brian J Potter; Catherine Beauregard; Omar Serri
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis.

Authors:  Rongqin Ren; Robert H Oakley; Diana Cruz-Topete; John A Cidlowski
Journal:  Endocrinology       Date:  2012-09-18       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.